The Manufacturers Life Insurance Company bought a new position in Avantor, Inc. (NYSE:AVTR – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 953,968 shares of the company’s stock, valued at approximately $9,444,000.
A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Avantor in the second quarter valued at approximately $695,784,000. Wellington Management Group LLP bought a new stake in Avantor during the 4th quarter worth approximately $268,584,000. Engine Capital Management LP lifted its stake in Avantor by 65.8% in the 1st quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock worth $155,082,000 after purchasing an additional 7,853,018 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in Avantor in the 2nd quarter worth approximately $195,386,000. Finally, Morgan Stanley boosted its holdings in Avantor by 179.4% in the 4th quarter. Morgan Stanley now owns 17,468,418 shares of the company’s stock valued at $200,188,000 after purchasing an additional 11,216,565 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Avantor Stock Down 0.1%
AVTR opened at $14.60 on Friday. The business’s fifty day simple moving average is $12.12 and its 200 day simple moving average is $9.77. Avantor, Inc. has a 52 week low of $7.26 and a 52 week high of $15.93. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The stock has a market cap of $9.87 billion, a PE ratio of -17.38, a P/E/G ratio of 11.00 and a beta of 0.89.
Analyst Upgrades and Downgrades
Several research firms recently commented on AVTR. Citigroup boosted their target price on Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Morgan Stanley raised their price target on Avantor from $10.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Evercore set a $10.50 price target on Avantor in a research report on Monday, July 6th. Wolfe Research raised Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $13.00 price objective on shares of Avantor in a research report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.
Get Our Latest Stock Report on Avantor
Avantor Profile
Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.
Avantor’s offerings are organized across two primary segments.
Read More
- Five stocks we like better than Avantor
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
